Form D · Pharmaceuticals
Tris Pharma, Inc.
Monmouth Junction, NJ · CIK 0001754826
Offering snapshot reported Oct 4, 2018 · SEC filing
- Reported sold
- $125M Offering amount: $167M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $15M Reported outside-investor minimum
- First sale
- Sep 21, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 4, 2018 | Initial | $125,000,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-322786
Source: Form D, filed Oct 4, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Peter Ciano | Executive |
| Smita Mehta | Director |
| Ketan Mehta | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
2033 Route 130
Monmouth Junction, NJ, 08852
Monmouth Junction, NJ, 08852